Mirae Asset Global Investments Co. Ltd. Has $48.22 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Mirae Asset Global Investments Co. Ltd. decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 6.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 86,880 shares of the company's stock after selling 6,091 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned about 0.10% of IDEXX Laboratories worth $48,223,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. OFI Invest Asset Management acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. bought a new stake in shares of IDEXX Laboratories during the 3rd quarter worth about $26,000. Altshuler Shaham Ltd bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at approximately $26,000. Geo Capital Gestora de Recursos Ltd acquired a new stake in IDEXX Laboratories in the 3rd quarter worth approximately $28,000. Finally, Covestor Ltd boosted its position in IDEXX Laboratories by 71.8% during the third quarter. Covestor Ltd now owns 67 shares of the company's stock worth $29,000 after purchasing an additional 28 shares during the period. Institutional investors own 87.84% of the company's stock.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, CFO Brian P. Mckeon sold 23,326 shares of the business's stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the sale, the chief financial officer now owns 29,718 shares of the company's stock, valued at approximately $16,939,557.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CFO Brian P. Mckeon sold 23,326 shares of the company's stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the sale, the chief financial officer now owns 29,718 shares of the company's stock, valued at approximately $16,939,557.18. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the company's stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the sale, the chief executive officer now directly owns 79,247 shares in the company, valued at approximately $45,377,624.67. The disclosure for this sale can be found here. Insiders have sold 43,524 shares of company stock valued at $24,871,960 in the last 90 days. 2.11% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently weighed in on IDXX. StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Wednesday, December 20th. William Blair reiterated an "outperform" rating on shares of IDEXX Laboratories in a research note on Friday, January 5th. Barclays increased their target price on IDEXX Laboratories from $605.00 to $655.00 and gave the company an "overweight" rating in a research note on Tuesday, February 6th. Piper Sandler lowered IDEXX Laboratories from an "overweight" rating to a "neutral" rating and set a $525.00 price target for the company. in a report on Tuesday, January 30th. Finally, JPMorgan Chase & Co. raised their price objective on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 6th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $591.50.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX traded up $1.44 during trading hours on Friday, hitting $519.54. 420,818 shares of the company traded hands, compared to its average volume of 359,633. The stock has a market capitalization of $43.15 billion, a price-to-earnings ratio of 51.59, a P/E/G ratio of 2.85 and a beta of 1.26. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39. The firm has a 50-day moving average of $548.56 and a 200 day moving average of $505.65. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.42.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating the consensus estimate of $2.12 by $0.20. The firm had revenue of $901.60 million during the quarter, compared to analysts' expectations of $891.88 million. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The business's quarterly revenue was up 8.8% compared to the same quarter last year. During the same period in the prior year, the company earned $2.05 EPS. On average, analysts forecast that IDEXX Laboratories, Inc. will post 11.15 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.